Sugi Predict

Sugi Predict / Compounds / SCHEMBL1348786

SCHEMBL1348786

SCHEMBL1348786

NS(=O)(=O)c1cc(Br)ccc1F

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 9/20 0.45
▸ CA1 P00915 7/20 0.45
▸ CA9 Q16790 6/20 0.45
▸ CA12 O43570 5/20 0.45
▸ CA4 P22748 2/20 0.43
▸ CA6 P23280 2/20 0.43
▸ ACLY P53396 1/20 0.41
▸ DGAT1 O75907 1/20 0.41
▸ APLNR P35414 4/20 0.41
▸ PTGES2 Q9H7Z7 2/20 0.39
▸ TET2 Q6N021 1/20 0.39
▸ CA7 P43166 2/20 0.39
▸ CA13 Q8N1Q1 1/20 0.39
▸ CA5A P35218 2/20 0.38
▸ CA14 Q9ULX7 1/20 0.38
▸ CA5B Q9Y2D0 1/20 0.38
▸ AKR1B1 P15121 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30714290 0.83 AKR1B1 (0.49) CA2CA1CA9CA12CA4
SCHEMBL1347919 0.83 AKR1B1 (0.49) CA2CA1CA9CA12CA4
SCHEMBL8053895 0.80 CA2 (0.54) CA2CA1CA9CA12CA4
SCHEMBL707997 0.79 WDR5 (0.42) ACLYDGAT1APLNRAKR1B1
SCHEMBL1790226 0.79 FLT1 (0.39) ACLYDGAT1APLNRAKR1B1
SCHEMBL28038557 0.79 ACLY (0.41) CA9CA12ACLYDGAT1APLNR
SCHEMBL1127112 0.78 PTGES2 (0.49) CA2CA1CA9CA12CA6
SCHEMBL29721599 0.78 PTGES2 (0.49) CA2CA1CA9CA12CA6
SCHEMBL1645034 0.77 CA1 (0.47) CA2CA1CA9CA12CA4
Hydrochloric Acid SCHEMBL1554456 0.77 PTGES2 (0.47) CA2CA1CA9CA12CA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025243317-A1 SUBSTITUTED BICYCLIC SULFONAMIDE DERIVATIVES AS MODULATORS OF CBL-B JUBILANT BIOSYS LIMITED (IN) 2025-11-27 — — WO disclosed
CN-119462605-A CYP11A1 inhibitor and application thereof 轩竹生物科技股份有限公司 2025-02-18 — — CN disclosed
EP-4313967-A1 KHK INHIBITORS GILEAD SCIENCES, INC. (US) 2024-02-07 — — EP disclosed
WO-2022212194-A1 KHK INHIBITORS GILEAD SCIENCES, INC. (US) 2022-10-06 — — WO disclosed
WO-2022187693-A1 COVALENT CDK2-BINDING COMPOUNDS FOR THERAPEUTIC PURPOSES UMBRA THERAPEUTICS INC. (US) 2022-09-09 — — WO disclosed
WO-2022011211-A1 DEOXYNOJIRIMYCIN DERIVATIVES AS GLUCOSIDASE INHIBITORS EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) 2022-01-13 — — WO disclosed
WO-2021068950-A1 AMIDE COMPOUND AND MEDICAL USE THEREOF AS STING INHIBITOR 中国药科大学 2021-04-15 — — WO disclosed
CN-107873031-B Benzoxazinone derivatives and analogs thereof as modulators of TNF activity UCB生物制药私人有限公司 2021-03-12 — — CN disclosed
US-10287299-B2 Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity UCB BIOPHARMA SPRL (BE) 2019-05-14 — — US disclosed
US-20180134728-A1 Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity UCB S.A. (BE) 2018-05-17 — — US disclosed
US-7238808-B2 Acetylenyl-pyrazolo-pyrimidine derivatives HOFFMANN-LA ROCHE INC. (US) 2007-07-03 — — US disclosed
US-20060217387-A1 Acetylenyl-pyrazolo-pyrimidine derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2006-09-28 — — US disclosed
WO-2006099972-A1 ACETYLENYL-PYRAZOLO-PVRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2006-09-28 — — WO disclosed
US-6300352-B1 FOR THERAPY OF ASTHMA ASTRAZENECA AB (SE) 2001-10-09 — — US disclosed
CN-1284074-A Novel compounds ASTRA ZENECA BRITISH LTD (GB) 2001-02-14 — — CN disclosed
EP-1037889-A1 NOVEL COMPOUNDS AstraZeneca UK Limited (GB) 2000-09-27 — — EP disclosed
CN-1257481-A Pyridine derivatives and pharmaceutical compositions containing them ASTRA PHARMA PROD (GB) 2000-06-21 — — CN disclosed
EP-0971892-A1 NOVEL PYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Astra Pharmaceuticals Limited (GB) 2000-01-19 — — EP disclosed
WO-1999029686-A1 NOVEL COMPOUNDS ASTRAZENECA UK LIMITED (GB) 1999-06-17 — — WO disclosed
WO-1998042670-A1 NOVEL PYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ASTRA PHARMACEUTICALS LTD. (GB) 1998-10-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134728-A1 Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity TNF, NFKBIA, TNFRSF1A CA2 3971/4885CA1 3838/4885CA9 3427/4885
US-20060217387-A1 Acetylenyl-pyrazolo-pyrimidine derivatives NAT1, TPMT, ACAT1 CA2 4071/4885CA1 3680/4885CA9 3708/4885
US-10287299-B2 Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity TNF, TNFRSF1A, NFKBIA CA2 3488/4885CA1 3557/4885CA9 3435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.